Sign in

You're signed outSign in or to get full access.

Natalie Biafori

Vice President and Equity Research Analyst at UBS

Natalie Biafori is a Vice President and Equity Research Analyst at UBS, specializing in the healthcare sector with a focus on biotechnology and pharmaceuticals. She covers specific companies including Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and BioMarin Pharmaceutical, achieving a strong performance track record with a 62% success rate on TipRanks and average returns of 18.5% per rating. Biafori joined UBS in 2021 after previous roles at Jefferies as a research associate from 2018 to 2021 and at Leerink Partners earlier in her career, holding a BS in Biology from Duke University. She maintains active FINRA Series 7 and 63 licenses, with no notable public awards but consistent recognition in institutional investor surveys for her biotech insights.

Natalie Biafori's questions to CYTOKINETICS (CYTK) leadership

Question · Q4 2025

Natalie Biafori, on behalf of Ashwani Verma, asked about the discontinuation rate in ACACIA-HCM compared to prior studies and the percentage of patients with the concentric LVH phenotype in the baseline population.

Answer

Fady Malik, EVP of R&D, stated that the study was designed to withstand a 10% discontinuation rate and remains within that metric. He could not comment on baseline characteristics like concentric LVH as they have not been released, but noted that HCM specialists review every echo for diagnosis consistency.

Ask follow-up questions

Fintool

Fintool can predict CYTOKINETICS logo CYTK's earnings beat/miss a week before the call

Question · Q4 2025

Natalie Biafori inquired about the discontinuation rate in ACACIA-HCM compared to prior studies and asked for the percentage of patients with the concentric LVH phenotype at baseline in the study population.

Answer

EVP and Chief Commercial Officer Andrew Callos stated that the study was designed to withstand a 10% discontinuation rate and remains within that metric. He added that baseline characteristics have not been released, but HCM specialist physicians review every echo to ensure consistency with hypertrophic cardiomyopathy.

Ask follow-up questions

Fintool

Fintool can write a report on CYTOKINETICS logo CYTK's next earnings in your company's style and formatting